SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : OSI Pharmaceuticals (OSIP) - formerly Oncogene

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Robohogs who wrote (435)1/14/2008 7:12:09 AM
From: scaram(o)uche  Read Replies (1) of 447
 
Jon:

SLV320 from Solvay, purchased by OSI from Cadus (verification from Solvay that the molecule originated at Cadus).

clinicaltrials.gov

I'll post more later, showing the trail. Goddard planned to spin out diabetes and the adenosine receptor program to Prosidion, and then all signs of a OSI/SLV320 relationship simply went *poof*. No sweat, but the OSI-Cadus deal bears milestone and royalty obligations. Unless, that is, Goddard, Glass and Icahn have conspired to make the molecule go away.

The *poof* actually pre-dated the Tarceva windfall, the only thing that has saved Goddard's sorry business development ass.

Best! Rick
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext